Common and Differentiated Representations Between Social Exclusion and Social Separation

NCT05920707 | Unknown

• 1 other identifier: UESTC-neuSCAN-93
• Study Type: interventional
• Target: 120
• Locations: 1 country
• Sites: 1

Brief Summary

Explore the shared or separated neural mechanisms of social exclusion and social segregation and compare differential effects of AVP and OXT on these social interaction function.

Conditions

Healthy

Keywords

Social exclusion; Social separation; Oxytocin; Arginine Vasopressin; fMRI

Outcome Measures

Primary Outcomes (2)

• Neural index: OXT and AVP effects on fMRI based- social exclusion and social separation tasks

  Comparions between OXT and AVP on social exclusion and social separation on brain activity or representations

  45 minutes after treatment administration

• Behavioral index: behavioral ratings of social exclusion and social separation tasks

  Comparions between social exclusion and social separation in pain ratings

  Immediately after fMRI scanning

Study Arms (4)

Intranasal Oxytocin

ACTIVE COMPARATOR

Administer oxytocin (24 IU) intranasally.

Drug: Intranasal Oxytocin

Intranasal Arginine Vasopressin

ACTIVE COMPARATOR

Administer Arginine Vasopressin (20 IU) intranasally.

Drug: Intranasal Arginine Vasopressin

Intranasal placebo

PLACEBO COMPARATOR

Administer placebo intranasally.

Drug: Intranasal placebo

Intranasal nothing (control)

NO INTERVENTION

Control condition

Interventions

Intranasal Oxytocin DRUG

Administer oxytocin (24 IU) intranasally, 6 individual 0.1 ml puffs (4 IU/0. 1ml), three puffs per nostril one every 30 seconds.

Intranasal Oxytocin

Intranasal Arginine Vasopressin DRUG

Administer arginine vasopressin (20 IU) intranasally, 6 individual 0.1 ml puffs (3.33 IU/0. 1ml), three puffs per nostril one every 30 seconds.

Intranasal Arginine Vasopressin

Intranasal placebo DRUG

Administer placebo intranasally, 6 individual 0.1 ml puffs, three puffs per nostril one every 30 seconds.

Intranasal placebo

Eligibility Criteria

• Age: 18 Years - 30 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Healthy subjects;
• Without any past or present psychiatric or neurological disorders;
• Without any current psychotherapeutic medication.

You may not qualify if:

• With any past or present psychiatric or neurological disorders;
• With any current psychotherapeutic medication.

Sponsors & Collaborators

• University of Electronic Science and Technology of China: lead

Study Sites (1)

University of Electronic Science and Technology of China(UESTC)

Chengdu, Sichuan, China

RECRUITING

MeSH Terms

Conditions

Social Isolation; Diabetes Insipidus

Condition Hierarchy (Ancestors)

Social Behavior; Behavior; Kidney Diseases; Urologic Diseases; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Male Urogenital Diseases; Pituitary Diseases; Endocrine System Diseases

Study Officials

• Siying Wang, Dr

  University of Electronic Science and Technology of China

  STUDY CHAIR

Central Study Contacts

Keith M Kendrick, Dr

CONTACT

+86-28-61830811; k.kendrick.uestc@gmail.com

Weihua Zhao, Dr

CONTACT

+8618780247797; zarazhao@uestc.edu.cn

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: TRIPLE
• Who Masked: PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: BASIC SCIENCE
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Associate Professor

Model Details: Randomized placebo-controlled double-blind between-subject design

Study Record Dates

• First Submitted: June 2, 2023
• First Posted: June 27, 2023
• Study Start: April 20, 2023
• Primary Completion: September 20, 2023
• Study Completion: October 1, 2023
• Last Updated: June 28, 2023

Record last verified: 2023-06

Locations

CN (1)